Topiramate in Long-Term Treatment of Epilepsy in the Intellectually Disabled

Autor/inn/en	Arvio, M.; Sillanpaa, M.
Titel	Topiramate in Long-Term Treatment of Epilepsy in the Intellectually Disabled
Quelle	In: Journal of Intellectual Disability Research, 49 (2005) 3, S.183-189 (7 Seiten)Infoseite zur Zeitschrift PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0964-2633
DOI	10.1111/j.1365-2788.2005.00637.x
Schlagwörter	Quantitative Daten; Patients; Seizures; Epilepsy; Incidence; Mental Retardation; Pharmacology; Pharmacy + Suchen Sie Ihr Suchwort? Patient; Anfallsleiden; Epilepsie; Vorkommen; Geistige Behinderung; Arzneikunde; Apotheke
Abstract	To study the effectiveness of topiramate (TPM) in refractory epilepsy in patients who have intellectual disability (ID). A representative population sample of 57 patients with ID (age range 261, mean 32.8) was administered add-on TPM for drug-refractory epilepsy. Results Seizure freedom for at least for 6months was attained by 10 (17%), and seizure reduction of 50% by further 26 (46%). Less than 50% decrease in seizure frequency was found in 16 (29%). TPM was more efficacious in localisation-related than in generalised epilepsies (81% vs. 50%, P0.019). An at least 50% decrease in seizure frequency was achieved by patients with temporal lobe epilepsy in 100%, continuous spikewaves during sleep syndrome in 75%, Lennox-Gastaut syndrome in 52%, and those with infantile spasms in 25% of cases. As great decrease in seizure frequency was found in most patients with cortical dysplasia (83%), acquired encephalopathy with mesial temporal sclerosis (MTS) (75%), and genetic disease associated with MTS (66%). Adverse effects occurred in 10% including two (3%) with seizure aggravation and three (5%) necessitating discontinuation. TPM is an effective antiepileptic drug which is of value in treating people with seizures that are resistant to other antiepileptic medication. As a broad-spectrum drug it may substitute for polypharmacy and, at the same time decrease adverse effects and costs of therapy. (Author).
Anmerkungen	Journal Customer Services, Blackwell Publishing, 350 Main Street, Malden, MA 02148. Tel: 800-835-6770 (Toll Free); Fax: 781-388-8232; e-mail: subscrip@bos.blackwellpublishing.com.
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10